TOIIW
TOIIW 1-star rating from Upturn Advisory

The Oncology Institute Inc (TOIIW)

The Oncology Institute Inc (TOIIW) 1-star rating from Upturn Advisory
$0.19
Last Close (24-hour delay)
Profit since last BUY-17.39%
upturn advisory logo
WEAK BUY
BUY since 30 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/12/2025: TOIIW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -61.06%
Avg. Invested days 31
Today’s Advisory WEAK BUY
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/12/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.16
52 Weeks Range 0.01 - 0.20
Updated Date 06/14/2025
52 Weeks Range 0.01 - 0.20
Updated Date 06/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -602.09

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -15.96%
Operating Margin (TTM) -9.49%

Management Effectiveness

Return on Assets (TTM) -17.66%
Return on Equity (TTM) -277.62%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 66946108
Shares Outstanding -
Shares Floating 66946108
Percent Insiders -
Percent Institutions -

About The Oncology Institute Inc

Exchange NASDAQ
Headquaters Cerritos, CA, United States
IPO Launch date 2020-06-04
CEO & Executive Director Dr. Daniel Virnich FACHE, M.B.A., M.D.
Sector Healthcare
Industry Medical Care Facilities
Full time employees 825
Full time employees 825

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.